BioMedNewsBreaks

MondayJul 25, 2022 12:05 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Urges Shareholders to Vote in Favor of Proxy Proposals for Upcoming Annual Meeting

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today urged shareholders to vote in favor of the proposals outlined in its definitive proxy statement for the upcoming annual shareholder meeting to be held Wednesday, July 27, 2022. Proposals include the authorization to increase the number of shares available for issuance by the company and the authorization for the board of directors to effect a reverse stock split of the outstanding shares of the company’s common stock, at a split…

Continue Reading

MondayJul 25, 2022 11:53 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Issues Update on Phase 2 EB Trial

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today provided an update on its phase 2 clinical trial using investigational drug INM-755 cannabinol (“CBN”) cream for the treatment of patients with epidermolysis bullosa (“EB”). Based on safety data of the first five adult patients who completed the phase 2 study, an independent data monitoring committee agreed it is safe to allow the enrollment of adolescent patients, defined as persons aged twelve to seventeen with EB. “We are pleased that the initial safety data from InMed’s phase 2 EB clinical trial has allowed…

Continue Reading

FridayJul 22, 2022 2:14 pm

BioMedNewsBreaks – Why QSAM Biosciences Inc. (QSAM) Is ‘One to Watch’

QSAM Biosciences (OTCQB: QSAM), a clinical-stage biotechnology company, is focused on bringing to market targeted therapeutic radiopharmaceuticals. “The company is committed to advancing the fight against cancer through the discovery, development and delivery of effective treatment options for adult and pediatric patients,” a recent article reads. “CycloSam(R), QSAM Biosciences’ initial technology, is a clinical-stage bone targeting radiopharmaceutical invented by world-renowned scientists at IsoTherapeutics Group LLC. … CycloSam is designed to selectively target sites of high bone mineral turnover to deliver a prescribed tumor-killing dose of radiation to the tumor sites while minimizing radiation exposure to nearby healthy tissue. These parameters…

Continue Reading

FridayJul 22, 2022 1:51 pm

BioMedNewsBreaks – Silo Pharma Inc. (SILO), UMB Collaborating on Potentially Significant Homing-Peptide Technology

Silo Pharma (OTCQB: SILO) earlier this year extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). “Silo’s partnership with UMB focuses on peptides used for investigating and treating the arthritogenic process or joint disease. Current treatment for arthritis has side effects that include nausea, vomiting, diarrhea, tinnitus, hair loss, seizures, fever, congestion, unusual lumps or masses, and more. OTC arthritis therapeutics, such as common NSAIDs, can produce stomach ulcers, dizziness and indigestion and can have…

Continue Reading

WednesdayJul 20, 2022 3:02 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Unlocking ‘New Frontiers of Discovery’ with Kernel Flow

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various conditions, has announced preliminary data from a feasibility study using Kernel Flow. The results indicate that ketamine-induced changes in functional connectivity last for several days after administration of the substance. “Kernel Flow is the first easy-to-use, wearable device that collects and measures real-time brain activity before, during and after a psychedelic experience. Using the device, the study successfully measured the neuro-effect of ketamine over 11 days, confirming changes in functional connectivity that are consistent with current scientific research,” a recent article reads.…

Continue Reading

WednesdayJul 20, 2022 2:42 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Expanding Patient Eligibility in Potentially Pivotal Berubicin Trial

CNS Pharmaceuticals (NASDAQ: CNSP) recently announced that its global clinical trial for a potentially pivotal brain cancer treatment will expand patient eligibility following an amendment to its protocol for the study. “CNS has been enrolling patients in its phase II clinical trial for novel drug candidate Berubicin, which has shown promise in fighting the aggressive brain cancer glioblastoma (‘GBM’),” explains a recent article. “The trial will compare Berubicin’s performance to the standard of care chemotherapy agent Lomustine, aiming to establish that Berubicin is at least as effective as Lomustine and potentially better because of Berubicin’s reported capacity to cross the…

Continue Reading

WednesdayJul 20, 2022 2:18 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Featured in Stock2Me Podcast

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. Two-time Olympic gold medalist Abby Wambach joins the latest podcast to speak on behalf of Odyssey Health, a medical technology company developing a drug/device combination intended to treat concussion. Wambach is a member of Odyssey’s sports advisory board, which aims to support the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. “I had a unique,…

Continue Reading

MondayJul 18, 2022 10:42 am

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Appoints Michael Woudenberg as Chief Operating Officer

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced its appointment of Michael Woudenberg as chief operating officer of the company, overseeing all day-to-day operations. Woudenberg previously served as senior vice president of chemistry, manufacturing and controls. For the past several years, he has been an integral part of InMed’s executive team, supporting multiple functions within the organization. Prior to joining InMed, Woudenberg had over 20 years of successful drug development, process engineering, GMP manufacturing and general management experience at all levels of various companies. “I would like to congratulate Mike…

Continue Reading

ThursdayJul 14, 2022 1:59 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Equipping Physicians, Individuals with Comprehensive Immune System Views

Aditxt (NASDAQ: ADTX) provides the AditxtScore(TM), a proprietary immune mapping technology designed to provide a personalized profile of the immune system. “Licensed from Stanford University, AditxtScore(TM) for COVID-19 is Aditxt’s first commercial product. It enables patients to know the level of protection that an immune response to the SARS-CoV-2 virus or vaccination confers them…The results may also influence the vaccine-hesitant populace to take the vaccine, particularly when it is determined that they are not protected by antibodies. Generally, the AditxtScore(TM) results offer information on whether an individual has antibodies that will protect them against the virus; if the antibodies are…

Continue Reading

ThursdayJul 14, 2022 11:20 am

BioMedNewsBreaks – Odyssey Health Inc.’s (ODYY) Spokesperson Brett Favre to Be Featured on RedChip Money Report(R)

Odyssey Health (OTC: ODYY), f/k/a Odyssey Group International Inc., will be featured in a new interview aired by RedChip Companies on The RedChip Money Report(R) on Bloomberg TV at 7 p.m. Eastern Time this Saturday, July 16. Bloomberg TV is available in an estimated 73 million homes across the U.S. In the exclusive interview, Odyssey Health’s spokesperson and Pro Football Hall of Fame quarterback Brett Favre discusses the major concussion he sustained in the final play of his professional career. Favre will share why he is proudly working to reduce and prevent concussions, the potential of Odyssey’s concussion treatment, and…

Continue Reading